Introduction
Cardiac involvement in patients with systemic lupus erythematosus (SLE) is not uncommon, with a reported prevalence of up to 75%. [1] [2] [3] The involvement ranges from asymptomatic to life-threatening, and may include pericardial, myocardial or endocardial disease, systolic or diastolic dysfunction, pulmonary hypertension, and valvular or coronary abnormalities. The baseline cardiac assessment of patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) for hematological malignancies usually includes a radionuclide technetium multigated acquisition (MUGA) scan or two-dimensional echocardiogram (2DE). Data from patients with hematological malignancies undergoing autologous and allogeneic HSCT suggest a higher risk of cardiac toxicity in patients with impaired cardiac function or heart disease before transplantation -and patients are generally excluded from undergoing transplant on this basis. 4, 5 For patients with severe SLE, however, cardiac involvement may be part of their disease manifestation, and hence should not necessarily preclude them from receiving this therapy. Since the first case of auto-HSCT for SLE reported by Marmont et al. 6 in 1997, the procedure has been performed increasingly worldwide. We previously reported on disease outcomes in patients undergoing auto-HSCT for SLE, 7 but did not evaluate the impact of auto-HSCT on cardiac function. Therefore, we undertook a retrospective analysis of patients with SLE who had undergone auto-HSCT in our institution to determine the prevalence and nature of cardiac abnormalities before transplantation, and the effect of auto-HSCT on cardiac status in these patients.
Patients and methods
Between April 1997 and January 2006, a total of 55 patients with SLE underwent auto-HSCT. All patients were recruited to study protocols approved by the US Food and Drug Administration and Institutional Review Board of Northwestern University, Chicago. After informed consent, the patients either had a pre-treatment 2DE or MUGA scan performed; along with electrocardiograms, chest radiographs, full clinical assessment and laboratory tests of disease activity. These patients' medical records were retrospectively reviewed for pre-transplant symptomatic cardiac disease and/or abnormal findings on standard radionuclide ventriculography or 2-dimensional echocardiography. All patients met at least 4 of 11 of the American College of Rheumatology 1982 revised criteria for a diagnosis of SLE. 8 Patients' eligibility criteria have been reported previously, 7 and there were no specific cardiac inclusion or exclusion criteria apart from a baseline left ventricular ejection fraction (LVEF) below 40%, unless impairment was attributed to SLE. Lupus disease activity was measured by the SLE disease activity index (SLEDAI). 9 Stem cells were mobilized with a combination of cyclophosphamide 2 g/m 2 and subcutaneous filgrastim. Peripheral blood stem cells (PBSC) were harvested via apheresis upon neutrophil recovery. The PBSC product was either lymphocyte depleted via CD34-positive selection (Isolex; Nexell, Irvine, CA, USA or Ceprate; Cellpro, Bothell, Washington, DC, USA) or unmanipulated. The conditioning regimen consisted of either intravenous cyclophosphamide 200 mg/kg over 4 days with 90 mg/kg of equine ATG over 3 days; or intravenous cyclophosphamide 200 mg/kg over 4 days with alemtuzumab 60 mg over 2 days. PBSC were re-infused 36 h after the completion of cyclophosphamide on day 0, and patients received subcutaneous filgrastim from either day 0 or day þ 6 until neutrophil recovery. Antimicrobial prophylaxis was with ciprofloxacin, valacyclovir or acyclovir, fluconazole or voriconazole, and co-trimoxazole or pentamidine. During the period of neutropenia, patients received intravenous cefepime or Piperacillintazobactam empirically. Fungal and pneumocystis jiroveci prophylaxis was continued for at least 6 months after auto-HSCT; while herpes virus prophylaxis was continued for 12 months. Packed red blood cell transfusions were administered when hemoglobin concentration fell below 8 g/100 ml or where clinically indicated; platelets were transfused when platelet counts fell below 20 Â 10 9 /l or where clinically indicated. All blood products were irradiated, filtered and cytomegalovirus-safe.
Patients were followed up at a minimum of 6 months and 12 months after transplant, then yearly thereafter. Patients with cardiac abnormalities before auto-HSCT had follow-up 2DE or MUGA scans performed serially. Where possible, these tests were performed at Northwestern Memorial Hospital, although some patients had them performed in other centers at their request.
Toxicity was graded according to standard National Cancer Institute-Common Toxicity Criteria version 2.0. Functional impairment attributable to cardiac dysfunction was classified according to the New York Heart Association (NYHA) functional classification. 10 
Results

Patient characteristics
In all, the records of 55 patients were reviewed. The PBSC product was CD34-selected in 51 patients who received cyclophosphamide/antithymocyte globulin as the conditioning regimen; unmanipulated PBSC was utilized in four patients who received cyclophosphamide/alemtuzumab as the conditioning regimen. Of 55 patients, 13 were found to have significant cardiac abnormalities, either clinically or on pre-transplant MUGA scan or 2DE. Of these 13 patients, 12 were female, and the median age at the time of auto-HSCT was 39.3 years (range 17.7-54.7 years). The median baseline SLEDAI was 20 (range , while that of all the 55 patients was 23. The median duration of follow-up was 24 months (8-105 months). Three of the patients are dead: two from SLE progression/relapse at 11.5 months and 19 months post-transplant, respectively, and the third following an accident at 8 months.
The indications for auto-HSCT among the 13 patients included nephritis (n ¼ 7), cerebritis (n ¼ 8), refractory cytopenia (n ¼ 4), antiphospholipid syndrome (APS) (n ¼ 8), pulmonary involvement (n ¼ 7), serositis (n ¼ 4) and cardiac dysfunction (n ¼ 2). Cardiac abnormalities were impaired left ventricular systolic function (n ¼ 6), pulmonary hypertension (n ¼ 4), mitral valve dysfunction (n ¼ 3) and large pericardial effusion (n ¼ 1). A summary of their pre-transplant characteristics is listed in Table 1 .
Progress of patients with cardiac abnormalities
No transplant-related or cardiac deaths occurred among the 13 patients. Significant non-hematological toxicities included fluid overload, infection and engraftment syndrome. Five patients experienced fluid overload during the mobilization or transplant course, of which two cases were of grade III to IV severity -requiring supplemental oxygen or mechanical ventilation. Apart from these episodes, the patients did not suffer any significant cardiac toxicity and tolerated the procedure well. Responses in SLE disease activity and cardiac function were generally noted within 6 months of the procedure.
Pre-transplant impaired left ventricular systolic function
Six patients had abnormal LVEF before transplant, of which four patients had generally mild and asymptomatic (LVEF 40-45%) impairment; they improved or remained the same after auto-HSCT (Table 2) . Two patients had significant left ventricular dysfunction. The first presented with orthopnea and dyspnea at rest (NYHA class IV) and required long-term supplemental oxygen therapy. The LVEF was 25%, with global hypokinesia and moderate mitral regurgitation (MR). Dobutamine stress echocardiography did not reveal ischemia, and the underlying etiology for cardiac dysfunction was attributed to lupus. Due to the potential cardiotoxicity of cyclophosphamide, the drug was attenuated by 25% for the conditioning regimen. Both mobilization and auto-HSCT procedures were well tolerated. An episode of severe hypoxemia with bilateral pulmonary infiltrates attributed to SLE pneumonitis and heart failure occurred at 5 months, requiring endotracheal intubation and mechanical ventilation that responded to pulsed methylprednisolone. At 12 months post-transplant, SLE was in remission, LVEF improved to 35%, MR diminished to mild, functional status improved to NYHA class II and oxygen therapy was no longer required. At 16 months post-transplant, however, investigations suggested relapse of SLE/APS; the patient eventually died suddenly of an APS-related stroke at 19 months. While the patient remained functionally NYHA II, no repeat cardiac evaluation had been performed between relapse and subsequent death; hence, the impact of relapse on LVEF could not be evaluated.
The second patient with clinically significant impaired LVEF had severe APS complicated by two previous myocardial infarctions -the last of which was 2 years before auto-HSCT. Consequently, pre-transplant LVEF was 30% although she was asymptomatic. No reversible ischemia was demonstrated on thallium stress radionuclide scan of the heart, and the patient underwent mobilization and conditioning chemotherapy without complication. Serial 2DE showed steady improvement in LVEF beginning 3 months after auto-HSCT. The most recent 2DE at 24 months post-transplant showed a normal LVEF of 60-65%, and the patient is in complete remission from SLE.
Pre-transplant valvular disease
Three patients had moderate to severe mitral valve dysfunction attributed to lupus-associated valvular damage (Table 3) . One patient had severe MR with four-pillow orthopnea and dyspnea at rest. Baseline 2DE revealed thickened mitral valve leaflets with fibrocalcified tips and decreased mobility, and LVEF increased to 70% due to MR. Cardiac catheterization and ventriculography confirmed a severe mitral regurgitant jet and a mildly stenotic mitral valve. Mitral valve replacement was recommended, but due to active lupus and high-dose corticosteroids (prednisone 120 mg/day) that would hinder wound healing and increase risk of infection, cardiovascular surgery was deemed too risky to undertake. Mobilization and transplant procedures were well tolerated, and functional status improved within 3 months after transplant from NYHA III to NYHA I. The most recent 2DE revealed movement of the posterior mitral valve leaflet that had been immobile before transplant. The patient is now more than 4 years post-transplant, in complete remission from SLE, remains asymptomatic from mitral disease and has not needed mitral valve surgery.
Another patient with severe MR was functionally in NYHA class IV before auto-HSCT with marked orthopnea -sleeping upright in a chair each night. Following Pre-transplant pulmonary hypertension Five patients had an elevated pulmonary artery systolic pressure (PASP) before transplant; median PASP 40 mm Hg (range 37-50 mm Hg) ( Table 4) . In two patients, the PASP improved or remained stable post-transplant with achievement of remission from SLE; one patient died at 8 months and PASP could not be quantified on 2DE performed at 6 months due to insufficient tricuspid regurgitation. In the remaining two patients, initial improvement was followed by increase in PASP, paralleling recurrent activity of underlying lupus. The first patient had coexistent SLE/APS with impaired pulmonary function and pulmonary hypertension (PASP 45 mm Hg with echocardiographic appearance of a volume-loaded right ventricle). She had initially achieved remission from SLE after transplant, and 2DE performed at 3 and 6 months, respectively, showed improvement of PASP to below 30 mm Hg and normalization of right ventricle dimensions. Nine months post-transplant, however, SLE/APS relapsed -and accompanying 2DE showed worsening of pulmonary hypertension (PASP 55-60 mm Hg) with a corresponding symptomatic deterioration in pulmonary function. The second patient had interstitial lung disease secondary to SLE with severe restrictive defect of pulmonary function before auto-HSCT, along with pulmonary hypertension (PASP 39 mm Hg). Following transplant, lupus improved in the initial 12 months and PASP remained stable (35 mm Hg at 12 months). Subsequently, recrudescence of disease activity at 18 months correlated with worsening in pulmonary pressure: PASP 67 and 65 mm Hg at 18 and 24 months, respectively, with right ventricular hypertrophy.
Pre-transplant pericardial effusion
Only one patient in our cohort had a large pericardial effusion. She had echocardiographic, but not clinical evidence, of tamponade before auto-HSCT. Transplant was well tolerated without requiring pericardiocentesis. A 2DE at 12 months showed mild-to-moderate effusion with no evidence of tamponade. The most recent 2DE, performed 2 years after transplant, shows resolution of the pericardial effusion.
Discussion
Cardiac involvement in SLE has a reported prevalence of up to 75%, with possible involvement of all components of the heart; it ranges in severity from asymptomatic to potentially life-threatening. 1,2 The spectrum of involvement includes valve lesions, particularly the mitral valve, in reportedly up to 75%, 11 myocardial dysfunction in up to 78%, 2 pericardial involvement in up to 55% 3 and coronary artery disease in up to 16%. 12 However, the data on SLE-related cardiac disease are limited: with most studies having relatively few patients, heterogeneity in terms of sites of involvement and methods of detection, and short duration of follow-up. The reported prevalence also varies with whether information is obtained based on clinical symptoms or autopsy studies; transthoracic or transesophageal echocardiography, or nuclear imaging.
13,14 Such heterogeneity renders interpretation of the impact of cardiac involvement on patient outcome and its relation to disease activity difficult. This study is limited by its relatively small numbers, as well as its retrospective nature. In addition, since improvement in cardiac function was unexpected, the modalities utilized to evaluate the heart were not standardized: some were investigated with MUGA scans and others, 2DE. Where possible, the 2DE was performed at Northwestern Memorial Hospital, although the reading was not blinded. What prompted this analysis was the observation that patients with cardiac dysfunction not only tolerated auto-HSCT, but also some even had cardiac function improve post-transplant. Furthermore, this is to our knowledge the first analysis on the safety and effects of auto-HSCT on cardiac dysfunction in patients with SLE, and of its prevalence among a population of patients with particularly severe/refractory lupus.
The proportion of our patients with abnormalities on cardiac investigations was approximately one-fifth, which is lower than the reported prevalence of cardiac involvement among all SLE patients in the literature. This is not a surprising finding since correlation between severity of lupus and presence of cardiac involvement has not been demonstrated in other studies. 13, 15 The potential cardiac toxicity of both autologous and allogeneic HSCT in patients with hematological malignancies and cardiac co-morbidities has been reported for decades, 5, 16, 17 with poor pre-transplant LVEF being associated with a higher incidence of cardiac morbidity and mortality in some studies. 18 As a result, patients with hematological malignancies and coexistent significant cardiac dysfunction are precluded from transplant. Unlike patients with hematological malignancies in whom internal organ dysfunction is uncommon, patients with severe autoimmune diseases frequently have cardiac involvement, which may or may not be clinically overt. Consequently, there has been concern of increased cardiac morbidity and mortality among patients with autoimmune diseases undergoing auto-HSCT. This concern led the European Group for Blood and Marrow Transplantation to issue a consensus statement regarding cardiotoxicity occurring during transplant for autoimmune diseases, and addresses the need for monitoring of cardiac status before and during HSCT. 19 We demonstrate that patients with lupus-related cardiac abnormalities can undergo auto-HSCT safely and, with disease remission, may experience improvement in ventricular or valvular function, and perhaps pulmonary hypertension as well.
In SLE, myocardial disease is seldom clinically overt, although autopsy studies suggest subclinical disease could be as common as 57%. 20 Echocardiographic evidence of abnormal left ventricular function may be found in up to 25% of patients. 21 While myocardial inflammation secondary to SLE occurs, other factors may play a role: accelerated coronary artery disease, 22 associated renal failure, steroid-induced diabetes mellitus, systemic infections or uncontrolled hypertension. The underlying etiology of left ventricular dysfunction among our six SLE patients was not certain, except for one patient with earlier history of two APS-related myocardial infarctions. These patients had negative functional testing for ischemia and absence of 'traditional' cardiac risk factors, suggesting the cardiac dysfunction may have been secondary to lupus. The ventricular function remained stable, and in fact improved, among those patients who achieved remission from lupus post-transplant. This shows the procedure may be performed safely despite baseline impaired LVEF, and may reverse cardiac dysfunction in lupus-related myocardial disease, since conventional treatment of lupus-related myocarditis is immune-suppression with either steroids or cyclophosphamide. 23, 24 There is no definitive modality of investigation to determine myocardial involvement by lupus however, and the diagnosis is one of exclusion of other causative factors. It is therefore uncertain which patients with abnormal LVEF will respond to the high-dose immunosuppression accorded by the transplant.
Two of the 13 patients experienced grade III to IV toxicity with pulmonary edema and required mechanical ventilation; they were among the cohort of patients treated when our auto-HSCT program was first initiated. 25, 26 Subsequently, by avoiding hyper-hydration in patients with underlying cardiac dysfunction or renal impairment, and utilizing bladder irrigation and mesna infusion, we encountered no further episodes of grade III to IV pulmonary edema. 7 Our patients also demonstrated improvement or stability of cardiac function despite exposure to high doses of cyclophosphamide. The cardiotoxicity of high-dose cyclophosphamide has been well described and is related to the acute dose and rate of administration 27, 28 rather than cumulative dose. Neither earlier repeated exposure to cyclophosphamide nor cardiac dysfunction -both often present in refractory lupus patients -is thus a contraindication to undergoing high-dose cyclophosphamide therapy and auto-HSCT, in terms of effects on cardiac function.
Valvular dysfunction in SLE is common and usually asymptomatic, although severe symptomatic dysfunction, usually MR, occurs in approximately 10% of SLE patients. 13 The etiology of valve dysfunction in SLE is likely related to endocardial inflammation with LibmanSacks endocarditis. Interestingly, no data to date support treating lupus endocarditis with immunosuppression, and hence the mechanism of observed response to auto-HSCT among our patients with valvular dysfunction is uncertain. The association between APS and severity of valvular dysfunction has been reported. Perez-Villa et al. 15 demonstrated that worsening valve function and eventual need for valve surgery were associated with higher anticardiolipin antibody titers, but not with activity of SLE. Since we had reported previously on induction of remission from APS among patients with SLE undergoing HSCT, 29 it is possible that this reduction in antiphospholipid antibodies may account for the improvement in valvular function observed. The number of patients with valvular dysfunction and coexistent APS in our cohort is too small to draw any reliable conclusions on this postulate. Of note, our patient with severe MR and APS did not have detectable anticardiolipin antibodies but a positive lupus anticoagulant pre-transplant; she achieved remission from both APS and SLE, and demonstrated improvement in valve mobility and function, obviating the need for valve replacement surgery.
Pulmonary hypertension is an uncommon direct complication of SLE, occurring in approximately 14% of patients. It has been treated with immunosuppression, including high-dose cyclophosphamide, with significant response among SLE patients. 30, 31 Given this response to immunosuppression, it would be anticipated that the immunoablation of auto-HSCT would have a positive effect on patients with pulmonary hypertension. Echocardiography as a modality of measurement of PASP is limited, as it is calculated based on the velocity of the tricuspid regurgitant jet, if any. This may not be present in all patients in sufficient amount to derive the PASP, and is subject to inter-observer variation. However, it is a non-invasive means of determining pulmonary artery pressures and widely-used in the literature. Bearing these limitations in mind, we found the PASP appeared to improve following auto-HSCT in two of our five patients, and appeared to progress in parallel with recurrent disease activity in those who relapsed. Further studies and evaluation of more patients using cardiac catheterization to assess right heart pressures would be required to confirm these findings.
Contrary to expectation, significant pericardial involvement among our patients was not common. The reported prevalence of pericardial effusions/pericarditis in SLE ranges from 9 to 58% on echocardiographic studies, and is usually asymptomatic and associated with active disease.
32,33 Pericardial tamponade is rare; 34, 35 and while our patient had echocardiographic evidence of tamponade, she was managed expectantly given the absence of clinical hemodynamic compromise. Serosal disease in SLE usually responds to immunosuppressive therapy, as occurred in our patient after auto-HSCT.
In summary, cardiac dysfunction in SLE may be due to disease-related inflammatory damage (lupus myocarditis) which has been shown to respond to immunosuppression. 23, 24 Pulmonary hypertension related to SLE has also been shown to respond to high-dose cyclophosphamide 31 and hence response to the lymphoablation of HSCT may be anticipated. On the other hand, the role of immunosuppression in Libman-Sacks endocarditis and lupus-related cardiac dysfunction is not clear. The APS and antiphospholipid antibodies have been reported to be correlated to valve dysfunction, with one prospective echocardiographic study 15 showing that patients with these antibodies developed valve lesions. Given that HSCT may induce remission from APS, 29 it may perhaps be that the patients' valvular function may improve due to this. As only two of our patients with valve lesions also had elevated antiphospholipid antibodies, and only one of them achieved serological remission, we are unable to postulate if this was the mechanism of observed improvement in valvular function in our patients.
Conclusion
Cardiac dysfunction in SLE occurs frequently and may be a cause of significant morbidity and mortality. We have successfully performed auto-HSCT in patients with pre-existent cardiac involvement without significant cardiac toxicity. We previously reported that lupus-related pulmonary dysfunction correlates with disease activity, improving with transplant-induced remission, and declining with disease recurrence. 36 We now find that patients with left ventricular systolic dysfunction, mitral valvular dysfunction and pulmonary hypertension tolerated the procedure well, and cardiac parameters improved following auto-HSCT if they achieved remission from SLE. Our experience suggests auto-HSCT may be safely performed in selected patients with SLE with cardiac dysfunction, and warrants prospective study in a larger cohort of SLE patients. It is hoped that with further study, the selection of which patients with cardiac abnormalities would stand to benefit from auto-HSCT and justify the potential risk will be made clearer.
